Pro Medicus Locks in A$90M Deal to Power Boston Health Giant’s Full Imaging Stack
Pro Medicus locks in A$90M deal with Beth Israel Lahey Health
Pro Medicus Limited (ASX: PME) has announced that its wholly-owned US subsidiary, Visage Imaging, Inc., has signed a 7-year, A$90M contract with Boston-based Beth Israel Lahey Health. The agreement covers a “full stack” deployment of the Visage 7 platform, including Visage 7 Viewer, Visage 7 Workflow, and Visage 7 Open Archive, delivered via a cloud-based implementation process.
The contract operates on a transaction-based licensing model with potential upside, and go-live is targeted for Q1 of the 2027 calendar year.
When big ASX news breaks, our subscribers know first
What’s included in the deal — and why it matters
Full stack, full cloud
The contract encompasses all three core Visage 7 products, making this a “full stack” deployment rather than a partial or modular engagement. Visage Imaging will complete the migration from Beth Israel Lahey Health’s legacy PACS archives to Visage 7 Open Archive, while Visage 7 will also provide enterprise distribution of images integrated into Beth Israel Lahey Health’s electronic health record (EHR).
Implementation will follow Visage’s proven cloud-based process, consistent with PME’s CloudPACS strategy. Planning commences immediately, with the rollout structured around a Q1 2027 go-live target.
Who is Beth Israel Lahey Health?
Beth Israel Lahey Health is a Boston-based healthcare system that brings together academic medical centres, teaching hospitals, and community and specialty hospitals. Key scale indicators include:
- 14 hospitals
- More than 4,700 physicians
- 39,000 employees
- Service area: Eastern Massachusetts and Southern New Hampshire
The scale and profile of this client positions it as a flagship win for Visage Imaging in the North American market, adding further weight to the company’s growing roster of major US health system clients.
Dr Sam Hupert, Chief Executive Officer, Pro Medicus
“Beth Israel Lahey Health provides extraordinary, cutting-edge patient care. They join an ever growing list of Visage 7 clients to opt for our fully cloud-based platform, which, as a result of our CloudPACS strategy, is becoming the standard in the North American healthcare IT market.”
Understanding Pro Medicus’ transaction-based model
Pro Medicus does not charge clients a flat licence fee. Instead, the company earns revenue based on the volume of imaging studies processed through its platform. This is what is referred to as a transactional licensing model: the more scans and studies a health system processes through Visage 7, the more revenue PME generates.
This structure differs from traditional software licensing, where a vendor charges a fixed upfront or subscription fee regardless of usage. For investors, the transactional model is structurally attractive because revenue scales naturally alongside client growth. A large health system processing an increasing volume of imaging studies over a multi-year contract translates directly into higher revenue for PME, without requiring additional contract negotiations.
In the context of this announcement, the A$90M figure represents the contracted base value over the 7-year term. The transactional model means actual revenue could exceed this figure if Beth Israel Lahey Health’s imaging volumes grow over the life of the contract. The cloud-based delivery model also lowers implementation friction and supports the Q1 2027 go-live target.
| Contract Detail | Value |
|---|---|
| Client | Beth Israel Lahey Health |
| Contract Value | A$90M |
| Term | 7 years |
| Go-Live Target | Q1 2027 |
| Products Covered | Full stack — Visage 7 Viewer, Visage 7 Workflow, Visage 7 Open Archive |
| Delivery Model | Cloud-based (CloudPACS strategy) |
| Licensing Structure | Transaction-based with potential upside |
The next major ASX story will hit our subscribers first
Pipeline momentum and what comes next
Dr Sam Hupert, Chief Executive Officer, Pro Medicus
“Our pipeline remains strong and spans all market segments. This deal is for our ‘full stack’ comprising all three core Visage products, namely viewer, workflow and archive, a trend we see continuing.”
Management’s commentary on the pipeline carries forward-looking significance. Dr Hupert is not characterising full-stack adoption as an isolated outcome; rather, he is identifying it as a continuing trend across PME’s client base and pipeline. For investors, this signals that the Beth Israel Lahey Health contract may be indicative of the types of engagements PME expects to see as its CloudPACS strategy matures in the North American market.
Key forward-looking points from the announcement include:
- Rollout planning begins immediately
- Go-live targeted for Q1 2027 calendar year
- Full-stack adoption trend cited as continuing across the pipeline
- Pipeline described as strong and spanning all market segments
Taken together, the combination of a long-duration contract, full-stack deployment, cloud delivery, and a transactional upside model reinforces PME’s positioning as a leading provider in the North American healthcare IT imaging market. The A$90M, 7-year deal with Beth Israel Lahey Health adds both revenue visibility and a high-profile reference client to the company’s growing portfolio.
Don’t Miss the Next Healthcare IT Winner
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of the market the moment announcements hit. Click the “Free Alerts” button at Big News Blast to start receiving alerts today.